- Report
- September 2021
- 143 Pages
Global
From €2634EUR$2,750USD£2,243GBP
€5268EUR$5,500USD£4,486GBP
- Report
- March 2021
- 143 Pages
Global
From €1317EUR$1,375USD£1,121GBP
€2634EUR$2,750USD£2,243GBP
- Report
- July 2019
- 21 Pages
Global
From €599EUR$625USD£510GBP
€1197EUR$1,250USD£1,020GBP
- Report
- December 2018
- 288 Pages
Global
From €1317EUR$1,375USD£1,121GBP
€2634EUR$2,750USD£2,243GBP
- Report
- October 2018
- 141 Pages
Global
From €599EUR$625USD£510GBP
€1197EUR$1,250USD£1,020GBP
- Report
- August 2018
- 86 Pages
Global
From €5699EUR$5,950USD£4,853GBP
- Report
- October 2019
- 189 Pages
Global
From €3975EUR$4,150USD£3,385GBP
- Report
- October 2018
- 370 Pages
Global
From €3975EUR$4,150USD£3,385GBP
- Report
- December 2020
- 164 Pages
Global
From €4741EUR$4,950USD£4,037GBP
- Report
- April 2022
- 233 Pages
Global
From €3051EUR$3,185USD£2,598GBP
€4358EUR$4,550USD£3,711GBP
- Report
- April 2023
- 110 Pages
Global
From €4550EUR$4,750USD£3,874GBP
- Report
- November 2023
- 77 Pages
France
From €3352EUR$3,500USD£2,855GBP
- Report
- April 2023
- 130 Pages
Global
From €4550EUR$4,750USD£3,874GBP
- Report
- April 2023
- 119 Pages
Global
From €4550EUR$4,750USD£3,874GBP
- Report
- August 2022
- 120 Pages
Global
From €4550EUR$4,750USD£3,874GBP
- Report
- August 2022
- 120 Pages
Global
From €4550EUR$4,750USD£3,874GBP
- Report
- May 2023
- 450 Pages
Global
From €4789EUR$5,000USD£4,078GBP
- Report
- May 2023
- 220 Pages
Global
From €2394EUR$2,500USD£2,039GBP
- Report
- April 2023
- 350 Pages
Global
From €3113EUR$3,250USD£2,651GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €3113EUR$3,250USD£2,651GBP
Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease.
Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs.
Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more